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Abstract 
As part of our ongoing research for anticancer agents, the synthesis of a library of tricyclic 
compounds using the Bridging Ritter reaction has been described in Chapter 2. Tricyclic imines 
82a-c and amines (90a-b, 91a-b) were synthesised in good yields (> 70%). Eleven alkaloid-
like compounds were successfully synthesised. 
Encouraged by the synthetic success described in Chapter 2, preparation of tricyclic 
caryophyllene derived alkaloid-like compounds was undertaken to provide new leads as 
described in Chapter 3. The synthesis focused on the use of β-caryophyllene 96 and 
caryophyllene monoepoxide 117 as key starting materials in the Ritter reaction. Treating 96 
and 117 with various nitriles under strong acidic conditions afforded optically active tricyclic 
amides of caryolane 119a-i and clovane 120a-d skeletons. The formation of these skeletons 
proceeded via the acid catalysed Wagner-Meerwein rearrangement. The rations of the two 
structures depended on the reactivity of the nitriles that led to the more kinetically stable of the 
two skeletons. Caryolane 119c and clovane 120c and 126c were further used to generate 
complex alkaloid-like compounds through sequential amide cleavage and reductive alkylation. 
A total of 30 caryophyllene derived alkaloid-like compounds were successfully obtained and 
subjected to antiproliferative assays. 
Chapter 4 describes the biological activities of the synthesised compounds described in Chapter 
2 and 3. In-house in vitro biological assays were used to assess the cytotoxicities of the 
synthesised compounds on breast cancer cell lines MCF-7 (ER+) as well as MDA-MB-231 
(triple negative). Compound 63 was selected by the US National Cancer Institute (NCI) for 
their standard cytotoxicity screening program. It was shown to have significant anti-cancer 
activities with IC50 in the μM range, across seven cancer types. The anti-cancer activities of 
82c were found to be selective towards the aggressive and more challenging to treat triple 
negative (MDA-MB-231) cell line while exhibiting no antiproliferative activities towards the 
 
 
xxi 
 
MCF-7 cells at the highest concentration tested (50 μM). The IC50 of compound 82c was 
determined to be 7.9 μM for the MDA-MB-231 cell line. Furthermore, 82c arrested cell cycle 
at the G2/M phase and induced apoptosis in a dose-dependent manner. Cytotoxicities of 
compounds 63 and 82c were tested against noncancerous mammalian cells (Vero cell line) and 
found to be approximately eight folds more selective towards MDA-MB-231 than the Vero 
cell line.  
From caryophyllene-derived compounds, eight compounds effectively decreased the 
proliferation and viability of MDA-MB-231, with observed IC50 values ranging from 3.0 – 55.3 
μM. Amongst the eight, 119c, 120c, and 126a were most active and selective towards the more 
aggressive triple negative (MDA-MB-231) over the MCF-7 cells. Furthermore, compounds 
119c, 120c, and 126a also altered the distribution of cells throughout the cell cycle, as well as 
the ability to induce apoptosis in the MDA-MB-231 cells. This observed selectivity towards 
the harder to treat triple negative breast cancer cells make these compounds more ideal drug 
candidates for further development. 
 
